期刊文献+

罗格列酮钠肠溶片的制备及质量控制 被引量:3

Preparation and Quality Control of Rosiglitazone Sodium Enteric-coated Tablets
原文传递
导出
摘要 目的:制备罗格列酮钠肠溶片并建立其质量控制方法。方法:以罗格列酮钠为主药制备制剂,采用高效液相色谱法测定其中主药的含量。结果:所制制剂为白色包衣片,检查符合2005年版《中国药典》中的相关规定;罗格列酮检测浓度的线性范围为10~83μg·mL^(-1)(r=0.999 9),平均回收率为99.64%(RSD=1.05%)。结论:该制剂制备工艺可行,质量可控。 RESULTS: OBJECTIVE: To prepare rosiglitazone sodium enteric- coated tablets and establish its quality control method The tablets were prepared with rosiglitazone sodium and the content of rosiglitazone was determined by HPLC. The preparation was white coated tablets with its property up to the standard stated in Chinese Pharmacopeia (2005 Edition) . The linear range of rosigtitazone was 10-83μg · mL ^-1 (r = 0.999 9) and its average recovery was 99.64% (RSD = 1.05% ) . CONCLUSION: The preparation process was proved to be feasible and the quality of the preparation was controllable.
出处 《中国药房》 CAS CSCD 北大核心 2009年第10期773-774,共2页 China Pharmacy
基金 重庆市自然科学基金资助项目(2006BB5286)
关键词 罗格列酮钠肠溶片 制备 质量控制 Rosiglitazone sodium enteric coated tablets Preparation Quality control
  • 相关文献

参考文献4

二级参考文献21

共引文献5

同被引文献19

  • 1张云美,潘永全,杨俊卿,尚剑川,周岐新.HPLC法测定犬体内罗格列酮药物动力学参数[J].四川动物,2005,24(1):90-93. 被引量:2
  • 2杨俊卿,邱红梅,尚京川,周岐新,高丽佳,徐蜀远.依替膦酸罗格列酮与马来酸罗格列酮的生物等效性研究[J].第三军医大学学报,2006,28(23):2343-2345. 被引量:3
  • 3佟健.泮托拉唑钠肠溶片工艺改进研究[J].锦州医学院学报,2006,27(6):83-84. 被引量:5
  • 4胡湘南.噻唑烷二酮金属盐类药物肠溶制剂及其制备方法[P].中国专利:CN101327198.2008-12-24.
  • 5Sahi J, Black CB, Hamilton GA, et al.Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition[J]. Drug Metab Dispos, 2003,31 (4) :439.
  • 6Theocharis S, Margeli A, Vielh P, et al.Peroxisome proliferator-activeated receptor-γ ligands as cell-cycle modulators[J].Cancer Treat Rev, 2004,30 (6) : 545.
  • 7Fuchtenbusch M, Standl E, Schatz H.Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus[J].Exp Clin Endoerinol Diabetes, 2000, 108(3) : 151.
  • 8Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings[J]. A dv Drug Deliv Rev, 2001,46 ( 1-3) : 3.
  • 9Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability[J]. Bioorg Med Chem Lett, 2009,19 (10) : 2 844.
  • 10Raskin P, Rendell M, Riddle MC, et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin treated type 2 diabetes[J].Diabetes Care, 2001,24(7) : 1 226.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部